Parsaclisib + Parsaclisib + Ruxolitinib + Parsaclisib + Parsaclisib
Phase 2Terminated 0 views this week 0 watching💤 Quiet
Interest: 24/100
24
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
MPN (Myeloproliferative Neoplasms)
Conditions
MPN (Myeloproliferative Neoplasms)
Trial Timeline
Feb 8, 2017 → Apr 29, 2022
NCT ID
NCT02718300About Parsaclisib + Parsaclisib + Ruxolitinib + Parsaclisib + Parsaclisib
Parsaclisib + Parsaclisib + Ruxolitinib + Parsaclisib + Parsaclisib is a phase 2 stage product being developed by Incyte for MPN (Myeloproliferative Neoplasms). The current trial status is terminated. This product is registered under clinical trial identifier NCT02718300. Target conditions include MPN (Myeloproliferative Neoplasms).
What happened to similar drugs?
0 of 1 similar drugs in MPN (Myeloproliferative Neoplasms) were approved
Approved (0) Terminated (0) Active (1)
Hype Score Breakdown
Clinical
12
Activity
0
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02718300 | Phase 2 | Terminated |
Competing Products
6 competing products in MPN (Myeloproliferative Neoplasms)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Ruxolitinib | Incyte | Phase 2 | 32 |
| Ruxolitinib + Anagrelide + Placebo + Placebo | Incyte | Phase 2 | 24 |
| itacitinib | Incyte | Phase 2 | 32 |
| Ruxolitinib + Placebo | Incyte | Phase 3 | 37 |
| Pemigatinib | Incyte | Phase 2 | 32 |
| Itacitinib + Ruxolitinib | Incyte | Phase 2 | 32 |